Nonsurgical Management of Hyperhidrosis

Thoracic Surgery Clinics

Volumn 18, Issue 2, 2008, Pages 141-155

  Gee, Sarah ^a   Yamauchi, Paul S ^b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Skin Care Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM CHLORIDE; ANTIPERSPIRANT AGENT; ATROPINE; BENZOYL PEROXIDE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIPHEMANIL METHYLSULFATE; FORMALDEHYDE; GLUTARALDEHYDE; GLYCOPYRRONIUM BROMIDE; INDOMETACIN; OXYBUTYNIN; PROPANTHELINE BROMIDE; SCOPOLAMINE; TANNIN;

ALBUMIN BLOOD LEVEL; BLURRED VISION; CRANIOFACIAL DEVELOPMENT; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DYSPHAGIA; HUMAN; HYPERHIDROSIS; INCIDENCE; INJECTION SITE PAIN; IONTOPHORESIS; PHYSICAL EXAMINATION; PHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SWEATING; THERAPY EFFECT; TREATMENT INDICATION; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CHOLINERGIC ANTAGONISTS; DERMATOLOGIC AGENTS; HUMANS; HYPERHIDROSIS; IONTOPHORESIS; NEUROMUSCULAR AGENTS;

EID: 41949097953     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2008.01.003     Document Type: Review

References (88)

1. Strutton D.R., Kowalski J.W., Glaser D.A., et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 51 2 (2004) 241-248
2. Eisenach J.H., Atkinson J.L., and Fealey R.D. Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc 80 5 (2005) 657-666
3. Lear W., Kessler E., Solish N., et al. An epidemiological study of hyperhidrosis. Dermatol Surg 33 1 Spec No (2007) S69-S75
4. Cinà C.S., and Clase C.M. The illness intrusiveness rating scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res 8 8 (1999) 693-698
5. Gossot D., Galetta D., Pascal A., et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thorac Surg 75 4 (2003) 1075-1079
6. Zackrisson T., Eriksson B., Hosseini N., et al. Patients with hyperhidrosis have changed grip force, coefficient of friction and safety margin. Acta Neurol Scand 117 4 (2008) 279-284
7. Ram R., Lowe N.J., and Yamauchi P.S. Current and emerging therapeutic modalities for hyperhidrosis, part 1: conservative and noninvasive treatments. Cutis 79 3 (2007) 211-217
8. Lowe P.L., Cerdan-Sanz S., and Lowe N.J. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg 29 5 (2003) 545-548
9. Hornberger J., Grimes K., Naumann M., et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 51 2 (2004) 274-286
10. Lowe N., Campanati A., Bodokh I., et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 151 6 (2004) 1115-1122
11. Solish N., Bertucci V., Dansereau A., et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 33 8 (2007) 908-923
12. Krogstad A.L., Mork C., and Piechnik S.K. Daily pattern of sweating and response to stress and exercise in patients with palmar hyperhidrosis. Br J Dermatol 154 6 (2006) 1118-1122
13. Sato K., Kang W.H., Saga K., et al. Biology of sweat glands and their disorders. II. Disorders of sweat gland function. J Am Acad Dermatol 20 5 Pt 1 (1989) 713-726
14. Bovell D.L., Corbett A.D., Holmes S., et al. The absence of apoeccrine glands in the human axilla has disease pathogenetic implications, including axillary hyperhidrosis. Br J Dermatol 156 6 (2007) 1278-1286
15. Kreyden O.P., and Scheidegger E.P. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Clin Dermatol 22 1 (2004) 40-44
16. Atkins J.L., and Butler P.E. Hyperhidrosis: a review of current management. Plast Reconstr Surg 110 1 (2002) 222-228
17. Soter N.A., and Baden H. Normal and abnormal eccrine sweat gland function. 2nd edition. In: Soter N., and Baden H. (Eds). Pathophysiology of dermatologic disease (1991), McGraw Hill, New York 211-234
18. Karaca S., Kulac M., Uz E., et al. Is nitric oxide involved in the pathophysiology of essential hyperhidrosis?. Int J Dermatol 46 10 (2007) 1027-1030
19. Swartling C., Naver H., Pihl-Lundin I., et al. Sweat gland morphology and periglandular innervation in essential palmar hyperhidrosis before and after treatment with intradermal botulinum toxin. J Am Acad Dermatol 51 5 (2004) 739-745
20. Manca D., Valls-Solé J., and Callejas M.A. Excitability recovery curve of the sympathetic skin response in healthy volunteers and patients with palmar hyperhidrosis. Clin Neurophysiol 111 10 (2000) 1767-1770
21. Sato K., Kang W.H., Saga K., et al. Biology of sweat glands and their disorders. I. Normal sweat gland function. J Am Acad Dermatol 20 4 (1989) 537-563
22. Ro K.M., Cantor R.M., Lange K.L., et al. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg 35 2 (2002) 382-386
23. Glaser D.A., Hebert A.A., Pariser D.M., et al. Primary focal hyperhidrosis: scope of the problem. Cutis 79 Suppl 5 (2007) 5-17
24. International Hyperhidrosis Society. Diagnosis guidelines. Available at:. http://sweathelp.org Accessed October 13, 2007
25. Bajaj V., and Langtry J.A. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol 157 1 (2007) 118-121
26. Sato K., Ohtsuyama M., and Samman G. Eccrine sweat gland disorders. J Am Acad Dermatol 24 6 Pt 1 (1991) 1010-1014
27. Benohanian A., Dansereau A., Bolduc C., et al. Localized hyperhidrosis treated with aluminum chloride in a salicylic acid gel base. Int J Dermatol 37 9 (1998) 701-703
28. Holzle E., and Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminum chloride hexahydrate solution. Br J Dermatol 100 (1984) 399-403
29. Goh C.L. Aluminum chloride hexahydrate versus palmar hyperhidrosis. Evaporimeter assessment. Int J Dermatol 29 5 (1990) 368-370
30. Torch E.M. Remission of facial and scalp hyperhidrosis with clonidine hydrochloride and topical aluminum chloride. South Med J 93 1 (2000) 68-69
31. Glent-Madsen L., and Dahl J.C. Axillary hyperhidrosis. Local treatment with aluminum-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine. Acta Derm Venereol 68 1 (1988) 87-89
32. Stolman L.P. Treatment of hyperhidrosis. Dermatol Clin 16 4 (1998) 863-869
33. Flarenda R., Binb T., Elmorec D., et al. A preliminary study of the dermal absorption of aluminum from antiperspirants using aluminum-26. Food Chem Toxicol 2 (2001) 163-168
34. Guillard O., Fauconneau B., Olichon D., et al. Hyperaluminemia in a woman using an aluminum-containing antiperspirant for 4 years. Am J Med 117 12 (2004) 956-959
35. Frankland J.C., and Seville R.H. The treatment of hyperhidrosis with topical propantheline-a new technique. Br J Dermatol 85 6 (1971) 577-581
36. Grimalt R., Tordera P.D., and Callejas M.A. Topical atropine sulfate for the treatment of axillary hyperhidrosis. J Cosmet Dermatol 5 4 (2006) 294-296
37. Shaw J.E., Abbott C.A., Tindle K., et al. A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia 40 3 (1997) 299-301
38. Laccourreye O., Bonan B., Brasnu D., et al. Treatment of Frey's syndrome with topical 2% diphemanil methylsulfate (Prantal): a double-blind evaluation of 15 patients. Laryngoscope 100 6 (1990) 651-653
39. Bergstresser P.R., and Quero R. Treatment of hyperhidrosis with topical methenamine. Int J Dermatol 15 6 (1976) 452-455
40. Canaday B.R., and Stanford R.H. Propantheline bromide in the management of hyperhidrosis associated with spinal cord injury. Ann Pharmacother 29 (1995) 489-492
41. LeWitt P. Hyperhidrosis and hypothermia responsive to oxybutynin. Neurology 38 3 (1988) 506-507
42. Schollhammer M., and Misery L. Treatment of hyperhidrosis with oxybutynin. Arch Dermatol 143 4 (2007) 544-545
43. Kuritzky A., Hering R., Goldhammer G., et al. Clonidine treatment in paroxysmal localized hyperhidrosis. Arch Neurol 41 11 (1984) 1210-1211
44. Feder R. Clonidine treatment of excessive sweating. J Clin Psychiatry 56 1 (1995) 35
45. Tkach J.R. Indomethacin treatment of generalized hyperhidrosis. J Am Acad Dermatol 6 4 Pt 1 (1982) 545
46. James W.D., Schoomaker E.B., and Rodman O.G. Emotional eccrine sweating. A heritable disorder. Arch Dermatol 123 7 (1987) 925-929
47. Sloan J.B., and Soltani K. Iontophoresis in dermatology: a review. J Am Acad Dermatol 15 4 Pt 1 (1986) 671-684
48. Sato K., Timm D.E., Sato F., et al. Generation and transit pathway of H+ is critical for inhibition of palmar sweating by iontophoresis in water. J Appl Physiol 75 5 (1993) 2258-2264
49. Karakoç Y., Aydemir E.H., Kalkan M.T., et al. Safe control of palmoplantar hyperhidrosis with direct electrical current. Int J Dermatol 41 9 (2002) 602-605
50. Dolianitis C., Scarff C.E., Kelly J., et al. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australas J Dermatol 45 4 (2004) 208-212
51. Shrivastava S.N., and Singh G. Tap water iontophoresis in palmo-plantar hyperhidrosis. Br J Dermatol 96 2 (1977) 189-195
52. Akins D.L., Meisenheimer J.L., and Dobson R.L. Efficacy of the Drionic unit in the treatment of hyperhidrosis. J Am Acad Dermatol 16 4 (1987) 828-832
53. Karakoc Y., Aydemir E.H., and Kalkan M.T. Placebo-controlled evaluation of direct electrical current administration for palmoplantar hyperhidrosis. Int J Dermatol 43 7 (2004) 503-505
54. Shen J.L., Lin G.S., and Li W.M. A new strategy of iontophoresis for hyperhidrosis. J Am Acad Dermatol 22 2 Pt 1 (1990) 239-241
55. Kavanagh G.M., and Shams K. Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. J Am Acad Dermatol 55 Suppl 5 (2006) S115-S117
56. Na G.Y., Park B.C., Lee W.J., et al. Control of palmar hyperhidrosis with a new "dry-type" iontophoretic device. Dermatol Surg 33 1 (2007) 57-61
57. Hallett M. One man's poison-clinical applications of botulinum toxin. N Engl J Med 341 2 (1999) 118-120
58. Cheng C.M., Chen J.S., and Patel R.P. Unlabeled uses of botulinum toxins: a review, part 1. Am J Health Syst Pharm 63 2 (2006) 145-152
59. Wenzel R.G. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm 61 22 Suppl 6 (2004) S5-S10
60. Yamauchi P.S., and Lowe N.J. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol 22 1 (2004) 34-39
61. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 6 (1997) S146-S168
62. Naumann M., Lowe N.J., Kumar C.R., et al. Hyperhidrosis Clinical Investigators Group. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 139 6 (2003) 731-736
63. Heckmann M., Ceballos-Baumann A.O., and Plewig G. Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344 7 (2001) 488-493
64. Campanati A., Penna L., Guzzo T., et al. Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther 25 1 (2003) 298-308
65. Nelson L., Bachoo P., and Holmes J. Botulinum toxin type B: a new therapy for axillary hyperhidrosis. Br J Plast Surg 58 2 (2005) 228-232
66. Baumann L., Slezinger A., Halem M., et al. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis. Int J Dermatol 44 5 (2005) 418-424
67. Dressler D., Adib Saberi F., and Benecke R. Botulinum toxin type B for treatment of axillary hyperhidrosis. J Neurol 249 12 (2002) 1729-1732
68. Lowe N.J., Glaser D.A., Eadie N., et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 56 4 (2007) 604-611
69. Lowe N.J., Yamauchi P.S., Lask G.P., et al. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 28 9 (2002) 822-827
70. Shelley W.B., Talanin N.Y., and Shelley E.D. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 38 2 Pt 1 (1998) 227-229
71. Solomon B.A., and Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 42 6 (2000) 1026-1029
72. Kinkelin I., Hund M., Naumann M., et al. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 143 4 (2000) 824-827
73. Laccourreye O., Akl E., Gutierrez-Fonseca R., et al. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome. Arch Otolaryngol Head Neck Surg 125 3 (1999) 283-286
74. Glaser D.A., Hebert A.A., Pariser D.M., et al. Facial hyperhidrosis: best practice recommendations and special considerations. Cutis 79 Suppl 19 (2007) 29-32
75. Klein A.W. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 22 1 (2004) 66-75
76. Glaser D.A., Hebert A.A., Pariser D.M., et al. Palmar and plantar hyperhidrosis: best practice recommendations and special considerations. Cutis 79 Suppl 19 (2007) 18-28
77. Saadia D., Voustianiouk A., Wang A.K., et al. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 57 11 (2001) 2095-2099
78. Wollina U., Karamfilov T., and Konrad H. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. J Am Acad Dermatol 46 4 (2002) 536-540
79. Naumann M., and Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20 7 (2004) 981-990
80. Naumann M.K., Hamm H., and Lowe N.J. Botox Hyperhidrosis Clinical Study Group. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 147 6 (2002) 1218-1226
81. Baumann L., Frankel S., Welsh E., et al. Cryoanalgesia with dichlorotetrafluoroethane lessens the pain of botulinum toxin injections for the treatment of palmar hyperhidrosis. Dermatol Surg 29 10 (2003) 1057-1059
82. Vadoud-Seyedi J., and Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 156 5 (2007) 986-989
83. Simonetta Moreau M., Cauhepe C., Magues J.P., et al. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 149 5 (2003) 1041-1045
84. Dressler D., and Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 13 Suppl 1 (2006) 11-15
85. Krogstad A.L., Skymne A., Pegenius G., et al. No compensatory sweating after botulinum toxin treatment of palmar hyperhidrosis. Br J Dermatol 152 2 (2005) 329-333
86. Naumann M., and Lowe N.J. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomized, parallel group, double blind, placebo controlled study. BMJ 323 (2001) 1-4
87. Talarico-Filho S., Mendonça D.O., Nascimento M., et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 33 1 Spec No (2007) S44-S50
88. Baumann L.S., and Halem M.L. Botulinum toxin-B and the management of hyperhidrosis. Clin Dermatol 22 1 (2004) 60-65